Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05557422 · ClinicalTrials.gov registry record
BD OneFlow CLPD Panel (BD OneFlow LST, and B-CLPD T1 to T4 Assays) on the BD FACSLyric System.
A clinical trial, sponsored by Becton, Dickinson and Company.
- Completed
- Registry status
- 322
- Enrollment target
NCT05557422: Completed study, sponsored by Becton, Dickinson and Company.
NCT05557422 is a clinical trial that has completed, run by Becton, Dickinson and Company. The registered enrollment target is 322 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05557422 has completed, sponsored by Becton, Dickinson and Company.
- COMPLETED
- Registry status
- 322 participants
- Enrollment target
Study Summary
Multi-site, prospective performance study to determine equivalency between the investigational CLPD Full Panel on the FACSLyric system versus the final clinical diagnosis.
Primary Outcome
Determine equivalence between the investigational OneFlow CLPD panel on FACSLyric system results analyzed by two independent experts versus the final clinical diagnosis for Normal (T-cell, B-cell, and NK-cell) or Abnormal (T-cell or B-cell or NK-cell) phenotype using leftover, hematologically abnormal specimens.
Interventions
- DIAGNOSTIC_TEST BD OneFlow LST, and B-CLPD T1 to T4 Assays
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 322 participants |
| Start Date | 2022-10-12 |
| Est. Completion | 2024-05-08 |
What the finished NCT05557422 record still lists
NCT05557422 is an observational study that tracks outcomes without assigning an intervention. The registered 322 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which BD OneFlow LST, and B-CLPD T1 to T4 Assays is the first listed.
NCT05557422 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05557422 about?
NCT05557422 is a clinical study titled "BD OneFlow CLPD Panel (BD OneFlow LST, and B-CLPD T1 to T4 Assays) on the BD FACSLyric System.". Multi-site, prospective performance study to determine equivalency between the investigational CLPD Full Panel on the FACSLyric system versus the final clinical diagnosis.
What is the current status of trial NCT05557422?
This trial is currently completed. The enrollment target is 322 participants. The study started on 2022-10-12. Estimated completion is 2024-05-08.
What interventions are being tested in trial NCT05557422?
The interventions under investigation include: BD OneFlow LST, and B-CLPD T1 to T4 Assays (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05557422?
This trial is sponsored by Becton, Dickinson and Company, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04090359 · 322 participants · Phase 4
Dual Mobility Acetabular Cups in Revision TJA
- NCT04924075 · 322 participants · Phase 2
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- NCT03715933 · 321 participants · Phase 1
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
- NCT05922878 · 321 participants · Phase 2
Study of ALTO-300 in MDD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI